Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
IMMUNODIAGNOSTIC SYSTEMS from Liège, company number BE0436921949, closed financial year 2025 with a result of € 577,381 after tax. For that financial year IMMUNODIAGNOSTIC SYSTEMS recorded revenue of € 12.8 million and equity of € 7.4 million. Compared with financial year 2024, the result moved from € 444,002 to € 577,381. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ 7.4 million
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 577,381
▲ 30% vs 2024
Profit after tax over the fiscal year.
€ 474,595
▲ 30% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 2.9 million.
People and assets in 2025
68.9
▲ 2.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4.8 million
▲ 3% vs 2024
€ 70,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 193,312
▲ 53% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2.3 million
▲ 24% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 116 days on average.
€ 965,709
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 8,566,073 | € 9,429,136 | € 11,603,324 | € 12,832,055 | ▲ 11% |
| Profit after taxes | € 98,326 | € 320,416 | € 444,002 | € 577,381 | ▲ 30% |
| Equity | € 6,040,075 | € 6,359,272 | € 6,802,111 | € 7,378,376 | ▲ 8% |
| Total debts | € 2,973,505 | € 2,547,938 | € 2,858,657 | € 3,313,877 | ▲ 16% |
| Cash | € 482,579 | € 240,064 | € 365,810 | € 474,595 | ▲ 30% |
| Land & buildings | € 305,259 | € 287,268 | € 269,381 | € 251,967 | ▼ 6% |
| Retained profit | € 1,530,782 | € 1,851,198 | € 2,295,200 | € 2,872,581 | ▲ 25% |
| Balance sheet total | € 9,013,580 | € 8,907,210 | € 9,660,768 | € 10,692,252 | ▲ 11% |
| Employees (FTE) | 64.9 | 64.4 | 66.2 | 68.9 | ▲ 2.7 |
Key figures of IMMUNODIAGNOSTIC SYSTEMS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IMMUNODIAGNOSTIC SYSTEMS?
What happened at IMMUNODIAGNOSTIC SYSTEMS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 577,381 (▲ 30% vs 2024). Source: NBB ↗
- Oscar Crasson became a director. NBB
- David Brésart stepped down as director. NBB
- Nicola Mitton stepped down as director. NBB
- Nicola Mitton became a director. NBB
- Edward Coombes became a director. NBB
- Dirk Beecker became a director. NBB
- David Brésart became a director. NBB
In short
From € 98,326 profit in 2022 to € 577,381 profit in 2025.
Paid € 760,158 in corporate taxes since 2022.
Best year ever: 2025, with € 577,381 profit.
Pays suppliers within 116 days on average.
A new publication or filing at IMMUNODIAGNOSTIC SYSTEMS? We notify you, reason included.
Follow IMMUNODIAGNOSTIC SYSTEMSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind IMMUNODIAGNOSTIC SYSTEMS are Edward Coombes, Dirk Beecker and Oscar Crasson.
Directors
According to the 2025 annual accounts
Edward Coombes
Director
since 2023
Dirk Beecker
Director
since 2023
Oscar Crasson
Director
since 2025
David Brésart
Director
since 2022 · until 2025
Nicola Mitton
Director
since 2024 · until 2025
Establishments
Establishment units
Physical locations of this company
Rue Ernest-Solvay 101
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Domain
Domain
idsplc.com
Registered
2008-03-12
Registrar
IONOS SE
Expires
2029-03-12
Website info
Features
Security
Network
Details
- Company number
- 0436.921.949
- VAT number
- BE 0436.921.949
- Registered office
- Rue Ernest-Solvay 101, 4000 Liège
- Names & denominations
- IMMUNODIAGNOSTIC SYSTEMS · IDS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 February 1989
- Peppol
- Active · Active since 31 Dec 2025
- Contact
- idsplc.com
- Activities · NACE
Vervaardiging van andere chemische producten, neg
Vervaardiging van overige chemische producten
Marktonderzoekbureaus
Markt- en opinieonderzoek